Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review

Cristhian A. Urzua1,2,3*, Carl P. Herborot Jr4, Masaru Takeuchi5, Ariel Schlaen6, Luz E. Concha-del-Rio7, Yoshihiko Usui8, Loreto Cuitino1,9 and Ioannis Papasavvas4

Abstract

Background: Appraisals of Vogt-Koyanagi-Harada disease (VKH) have become progressively more complete, since its first description in 1906. The availability of new investigational methods has improved our knowledge of the immunopathology, clinicopathology, diagnosis, and management of VKH disease. This review aimed to describe some of the steps that led to better characterization of VKH as a clinical entity.

Methods: We searched on PubMed for articles that described the history of VKH disease and analyzed the progress in disease appraisal with new investigational and imaging methods. In particular, we searched for articles that investigated the clinicopathology, diagnosis, and management of VKH.

Findings: The following developments were considered essential for improving the appraisal and understanding of VKH: (1) the history of the disease, (2) immunopathological mechanisms, (3) clinicopathology, (4) the importance of distinguishing initial-onset from chronic disease, (5) relevant imaging modalities, among which indocyanine green angiography is crucial, (6) diagnostic criteria that facilitate early diagnosis, and (7) the need for early, prolonged, aggressive treatment that combines steroidal and non-steroidal immunosuppression.

Conclusion: Based on these findings, the definition of VKH has improved. VKH disease starts in the choroidal stroma and later involves other structures when it is not diagnosed and treated early. Indocyanine green angiography and enhanced depth imaging optical coherence tomography facilitate early diagnosis and precise monitoring of choroidal inflammation. ICGA is clearly the gold standard for appraisals and follow-ups in VKH disease, however EDI-OCT should be especially considered in those areas where ICGA is not fully available. These modalities have contributed substantially to a “cure” for VKH, when treatment is introduced within the therapeutic window of opportunity.

Keywords: Chronic VKH, Initial-onset acute VKH, Vogt-Koyanagi-Harada disease, Uveomeningoencephalitic syndrome

Introduction

Vogt-Koyanagi-Harada disease (VKH) was first described by Alfred Vogt in 1906 [1, 2]. Vogt’s case description focused principally on eyelash whitening (poliosis) [1]. The article was 14 pages long, and only five lines were devoted to intraocular inflammation [2]. Since that first publication, the appraisal of VKH disease has
progressively improved, step by step, up to very recent years. The purpose of this comprehensive global review was to describe the major advancements in the knowledge of VKH disease. VKH disease was defined as “... a rare, granulomatous inflammatory disease that affects pigmented structures, such as the eye, inner ear, meninges, skin, and hair” [3]. VKH starts in the eye; specifically, in the melanocyte islets of the choroidal stroma, which leads to the development of primary stromal choroiditis [4]. Failure to treat VKH in the early stage allows the inflammatory process to extend to other ocular structures, including the optic disc and retina; as VKH progresses, granulomatous panuveitis and chronic disease develop [4]. Previously, VKH disease progression was classified as probable (ocular involvement), incomplete (ocular plus integumentary involvement), and complete (ocular plus integumentary plus neurological involvement). Due to the moderate agreement on the diagnostic criteria for VKH and the implications of an early diagnosis on prognosis and disease resolution, our group recently proposed that two distinctive courses can be distinguished in a clinical evaluation of patients with VKH. This proposal was part of a pioneering, pragmatic advancement. These two clinical phenotypes should be identified early; they are known as initial-onset (acute) VKH and chronic (recurrent) VKH [5–7].

This comprehensive review starts from the perspective of a brief historical account; then, we address the more recent advancements in the appraisal of VKH disease. We cover the topics of immunopathology, clinicopathology, the crucial distinction between initial-onset and chronic disease, new imaging modalities, strong and improved diagnostic criteria, and VKH management.

Brief history of VKH disease

After the inaugural article by Alfred Vogt in 1906 [1], several patients with VKH were described in Japan. The first was published by Professor Jujiro Komoto in 1911 (in German) [8]. In 1914, Yoshizo Koyanagi described 2 cases published in the Japanese journal, Nippon Ganka Gakkai Zashii [9]. However, the ground-breaking article was published by Yoshizo Koyanagi in the German journal, Klinische Monatsblätter für Augenheilkunde, in 1929. That report described 16 cases of VKH disease, where he revealed the natural course of the disease. At the time, to gain international exposure, Japanese authors mostly published in German journals, because the medical doctrine and structure were built on the German system; many professors and numerous doctors completed their training in Germany. Koyanagi passed away in 1954 and was buried in Sendai, after having been dissuaded from his wish to have his ashes spread in the Bay of Matsushima, off Sendai.

Fig. 1  Yoshizo Koyanagi (1880–1954). Yoshizo Koyanagi was born in the Tokyo area in 1880. He graduated from Kyoto Imperial University, one of the seven imperial universities founded after the Meiji restoration and modernization of Japan, at the end of the 19th and beginning of the twentieth century. These universities were established in Tokyo (1886), Kyoto (1897), Tohoku University in Sendai (1907), Kyûshû University in Fukuoka (1911), Sapporo (1918), Osaka (1931) and Nagoya (1939). In 1914, Koyanagi published the first article in Japanese on the disease that would eventually bear his name. He described two patients with all the characteristics of VKH disease. In 1915, he became the first Professor of Ophthalmology of Tohoku Imperial University in Sendai, 300 km north of Tokyo. The lower part of the figure shows the title page of his ground-breaking article, which was published in the Klinische Monatsblätter für Augenheilkunde, in the German language. That article described 16 cases of VKH disease, where he revealed the natural course of the disease. At the time, to gain international exposure, Japanese authors mostly published in German journals, because the medical doctrine and structure were built on the German system; many professors and numerous doctors completed their training in Germany. Koyanagi passed away in 1954 and was buried in Sendai, after having been dissuaded from his wish to have his ashes spread in the Bay of Matsushima, off Sendai.

VKH disease, which he called acute diffuse choroiditis (choroiditis diffusa acuta; Fig. 2) [11].

The final eponym was coined by Professor Jean Babel of Geneva, who joined the names Vogt and Koyanagi in a proposal to call the disease Vogt-Koyanagi syndrome (disease). At that time, it was known that Harada’s disease and Vogt-Koyanagi syndrome were nearly identical [12]. By 1970, the majority of articles published used the term Vogt-Koyanagi-Harada disease (syndrome), and by 2003, most authors had adopted the term Vogt-Koyanagi-Harada disease [13].
Advances in immunopathogenic mechanisms
The exact etiology of VKH disease is unknown. However, T cell-mediated autoimmune responses against melanocyte-related antigens are thought to be involved in VKH development. Several studies showed that peripheral blood mononuclear cells (PBMCs) from patients with VKH disease recognized peptides derived from the tyrosinase family of proteins (TYR, TRP1, and TRP2) which participate in melanin synthesis [14–17]. When mice were immunized with tyrosinase-related peptides, ocular inflammation was induced, which resembled VKH [18].

T cells initiate an immune response when they recognize antigen-derived peptides bound on major histocompatibility complex (MHC) molecules (also known as human leukocyte antigens [HLA]). The two primary types of MHC/HLA molecules involved in antigen presentation are known as MHC class I and II molecules. MHC class I molecules principally present peptides that are synthesized intracellularly, and they present them to T cytotoxic (Tc) cells. In contrast, MHC class II molecules present peptides derived from proteins taken up and degraded by the cell, and they present them to T helper (Th) cells [19]. Immunohistochemical studies of eyes with VKH revealed that T cells infiltrated into the choroid, and MHC class II molecules were found on choroidal melanocytes and on the endothelium of the choriocapillaris [20]. Although every human inherits a set of genes for MHC class I and II molecules, remarkable variability exists in each individual's MHC type. Several studies have indicated that MHC class II molecules, HLA-DRB1*0405 and DRB1*0410, were robustly related to VKH susceptibility [21]. That finding suggested that peptides derived from tyrosinase-family proteins preferentially bind to the HLA-DRB1*0405 and DRB1*0410 molecules, and they are presented at the cell surface of antigen-presenting cells [16, 17]. Among the Th-cell subsets that recognize MHC class II-associated antigens, Th1 cells produce interferon-gamma [16, 17] and Th17 cells produce IL-17 [22–24]. It was shown that Th1 and Th17 cells might be involved in pathological changes associated with VKH disease, such as choroidal stroma inflammation in the acute phase of VKH. In contrast, regulatory T cells, which produce IL-10 and TGF-β, were associated with the resolution of active inflammation in VKH [25, 26].

Clinical considerations and the distinction between initial-onset and chronic VKH
In VKH, inflammation starts exclusively in the choroidal stroma. This inflammation is triggered by an autoimmune reaction against melanocyte-associated antigens [27]. The pathogenesis of autoimmune diseases is complex and can manifest with significant differences among patients. Moreover, a comprehensive review on refractory rheumatoid arthritis suggested that treatment-resistance may arise from inflammatory or non-inflammatory mechanisms, and that these mechanisms lead to differential responses to disease-modifying anti-rheumatic drugs and outcomes. Those findings established that there were two different courses of rheumatoid arthritis [28]. In addition, other pathologies such as juvenile idiopathic arthritis and multiple sclerosis, have different clinical courses, and the therapeutic approach is different in each case [29, 30]. Consequently, making a clear distinction between different disease courses is fundamental to understanding and managing the disease [28]. Accordingly, two different VKH phenotypes were found in the literature: one was called initial-onset VKH and the other was called chronic VKH. These two subtypes showed remarkably different responses to treatment [31, 32]. Therefore, for VKH...
management, a clear distinction between initial-onset and chronic disease is a primary criterion for tailoring treatment.

Recent studies have provided compelling evidence on successful treatments for initial-onset VKH. Those studies represented a critical milestone in achieving disease resolution. For example, among patients with VKH that displayed an impaired response to corticosteroids, immunomodulatory therapy was beneficial, and it produced the greatest impact on visual acuity when patients started the treatment early after VKH onset [33]. Moreover, mycophenolate mofetil effectively improved choroid and optic nerve head blood flow in patients with initial-onset VKH without anterior inflammation [34]. Additionally, in patients that did not develop a sunset glow fundus, immunomodulatory therapy resolved the retinal oxygenation issues and blood vessel lumen changes that commonly occur in initial-onset VKH. However, in patients that developed a sunset glow fundus and choriotreital atrophy, immunomodulatory therapy did not alter impaired oxygen saturation [35–37]. Those studies have shown that detecting VKH at initial onset constituted a prognostic factor for a good response to immunomodulatory therapy.

Accurate discrimination between initial-onset and chronic-recurrent VKH requires a well-defined set of criteria. When applied, these criteria might provide some insight on how to differentially treat the two disease courses. Thus, a system of diagnostic criteria was developed and tested in a cohort of Chinese patients with VKH. Those criteria yielded a substantial improvement in sensitivity and negative predictive value, compared to the Revised Diagnostic Criteria for VKH disease from 2001 [38]. Moreover, based on those criteria, early- and late-phase VKH were recognized as clinically different conditions, which required different ancillary tests, such as fluorescein angiography (FA) and enhanced depth imaging optical coherence tomography (EDI-OCT), for evaluations of inflammation-related findings [38]. A recent review (2021) on the appraisal and management of initial-onset VKH [39] introduced a new means of assessing choroiditis: indocyanine green angiography (ICGA), and EDI-OCT as a surrogate. Thus, ICGA was added to the list of proposed criteria for diagnosing VKH.

A review by Herbort et al. also recommended the combined use of corticosteroids and non-steroidal immunosuppression for the management of initial-onset VKH [39, 40]. Additionally, dual corticosteroid and immunomodulatory therapy was shown to be successful in managing VKH; indeed, most patients remained in remission, even after discontinuing treatment [39]. Lately, these ancillary tests have been considered highly important for performing a complete clinical evaluation and for determining individually-tailored treatments for reducing the risk of inflammatory recurrences.

**Description of initial-onset and chronic VKH disease**

Prodromal findings of VKH can be neurological, auditory, and head skin dysesthesia manifestations. The symptoms include fever, meningismus (headache, malaise, nausea, stiffness of the neck and back), audiovestibular manifestations (sensorineural hearing loss, tinnitus, aural fullness, and vertigo), hyperesthesia of the scalp or orbital pain [6, 41]. These symptoms anticipate ocular disease, and they arise from a combination of choroidal and meningeal inflammation, which can only be detected with ICGA [42] and a CSF evaluation [43]. This stage lasts for a number of days, but it is not always present [41].

VKH inflammation starts solely in the choroidal stroma [32]. Clinical manifestations occur when choroidal inflammation has disseminated toward the surrounding tissues, such as the optic disc, retina, ciliary body, and anterior chamber. In the initial-onset of acute VKH, bilateral panuveitis develops, mainly with serous retinal detachment, papillitis, and mild to moderate vitritis. When this condition is not treated, it progresses to involve the anterior segment, and changes in the ciliary body may cause a shallow anterior chamber [44, 45].

VKH occurs bilaterally; however, the effects may be asymmetric [46]. For instance, a unilateral retinal detachment that occurs at onset can evolve into bilateral retinal detachment, when not appropriately treated [47]. Prompt detection of the disease with adequate choroidal evaluation is fundamental. ICGA was shown to identify choroidal granulomas in 100% of patients with initial-onset acute VKH [48]; alternatively, similar efficacy is probably achievable with EDI-OCT. When classical signs are present, inflammation can be found with various modalities, including laser flare photometry, FA, EDI-OCT, and ICGA [49].

One study, based on FA and OCT, classified VKH serous retinal detachments (SRDs) into two types: a clinical SRD and an optic-disc swelling type (OD-SRD). The OD-SRD type is very mild, with no subretinal fluorescein pooling. OD-SRD type VKH was associated with older age, longer times to treatment, and a higher likelihood of developing chronic disease. The pathological mechanism of OD-SRD is related to aging, which reduces the choriocapillaris density and changes disc morphology. Therefore, FA can anticipate the course of the disease and facilitate treatment planning [50].

The therapeutic “window of opportunity” for VKH [45] is 2 to 4 weeks after onset. When treatment is not initiated appropriately, the disease will progress to chronic
VKH. Chronic VKH differs from initial-onset VKH, in terms of the clinical signs, progression, treatment outcome, and the incidence of complications [40]. However, despite early administration of high-dose corticosteroids in the initial acute stage, 22.5% to 79% of patients can develop chronic VKH.

Chronic VKH is often characterized by a sunset glow fundus, and it occurs after 2–6 months. Among patients with chronic VKH, 38% progress to subretinal fibrosis [50–53]. Mild inflammation often persists, even when systemic steroid therapy is properly administered in the early stage of onset, and after the inflammation seems to be resolved. Exacerbations of VKH often occur in the form of chronic recurrent granulomatous anterior uveitis. Importantly, a significant correlation was found between anterior chamber activity and choroidal thickening, which may represent subclinical inflammation at the level of the posterior segment [6, 41, 54]. In those cases, ICGA may show evidence of choroidal inflammation (e.g., hypofluorescent dark dots), an indication that treatment adjustments should be considered.

In chronic VKH disease, depigmentation of the choroid makes the fundus appear red, known as a sunset glow sign. This sign appears in 60–70% of patients, and it appears more commonly in Asian patients [41]. Additionally, the atrophy of cells around the fundus causes a white patchy appearance, which is accompanied by local depigmentation of retinal pigment epithelial (RPE) cells. This feature is often confused with Dalen-Fuchs nodules, but the Dalen-Fuchs nodule is a granuloma pathologically formed by RPE and inflammatory cells. Consequently, the patchy atrophic lesions observed in the fundus are called scars of Dalen-Fuchs-like nodules [55]. Chronic VKH is also associated with complications that threaten vision, like cataract, glaucoma, choroidal neovascular membranes, subretinal fibrosis, and choroidal atrophy [41, 54, 56]. Accordingly, various studies have reported that chronic VKH was associated with poor visual acuity and reduced retinal sensitivity [44, 57].

**Imaging methods for diagnosing and monitoring VKH disease**

The appraisal of inflammation in posterior uveitis with imaging has made significant advances since the 1990s. However, modalities immediately relevant for the diagnosis and follow-up of stromal choroiditis must be distinguished from modalities that are interesting for investigational research, but ill-adapted and/or insufficiently standardized for diagnostic and/or follow-up purposes. A selection of new imaging modalities may be technically very elaborate, but inappropriate for investigating structures that they were not designed to image.

Fundus photography is part of the routine imaging work-up for VKH disease. In acute disease, fundus photography shows exudative retinal detachments. During follow-up in chronic disease, fundus photography shows Dalen-Fuchs like nodules, and it is crucial in portraying depigmentation of the fundus (i.e., a sunset glow fundus; Fig. 3) [58, 59].

**Fluorescein angiography**

Fluorescein angiography (FA) cannot show choroidal inflammation. However, in the acute exudative phase, FA can show spill-over inflammation which extends from the choroid to the retina and the optic disc. Recent diagnostic criteria for initial-onset VKH include two FA findings: exudative retinal detachment and disc hyperfluorescence [39, 60]. Characteristic signs include, initially, focal areas of delay in choroidal perfusion and choroidal folds, which appear as long, hypofluorescent lines that radiate from the optic nerve. Subsequently, multiple hyperfluorescent pinpoints and progressive subretinal pooling delineate exudative retinal detachments. These conditions lead to disc hyperfluorescence (Fig. 4) [61, 62] and vascular hyperfluorescence [63].

Peripapillary hyperfluorescent pinpoints can be observed in the hyperacute phase. Failure to observe this sign may imply that the FA was performed at a later stage, and thus, a more aggressive, prolonged regimen of immunosuppressive therapy would be required [64]. Additionally, hyperfluorescent lesions detected with FA were correlated with RPE detachments detected with spectral domain optical coherence tomography (SD-OCT) [65].

A recent study with ultra-wide field FA (UWF-FA) identified several uncommon features of VKH in the central and peripheral retina. Those results indicated that focal leakage occurred in 92.3%, pooling with a dark rim occurred in 84.6%, and vasculitis occurred in 46.2% of patients with VKH. Overall, UWF-FA detected 76.9% of the abnormal findings that could be identified with ICGA. Peripheral vascular leakage arises from choroidal inflammation. Thus, UWF-FA provides more data than conventional FA, and it can be used to evaluate responses to treatment and prognosis [66].

In the chronic phase of VKH, FA shows window defects in areas where RPE cells are lost, or a fluorescence-blocking effect in areas of pigment clumping from destroyed RPE cells. FA can also clearly show the limits of exudative detachments during the acute phase after reattachment (high water marks), which appear as hyperpigmented lines (Fig. 5) and disc hyperfluorescence [64]. Another sign of scarring is the appearance of dot-like, equatorial hyperfluorescence [63].
FA can facilitate the diagnosis of several complications, including arteriovenous and retinochoroidal anastomoses, optic disc neovascularization, and choroidal neovascularization [63].

**Optical coherence tomography**

SD-OCT is an advantageous imaging modality, because it is non-invasive; therefore, it can be repeated without risk. In its normal mode (retinal OCT), it allows the visualization of sections through the different retinal layers up to the RPE. In 2008, EDI-OCT was first described. EDI-OCT provides an image of the choroid and, in particular, the ability to measure choroidal thickness [67]. The current instruments used in clinical practice are limited, because they can only image the posterior pole. This is not a problem, when analyzing acute exudative retinal detachments in VKH, which occur mostly in the posterior pole. However, it represents a handicap for monitoring occult choroidal inflammation; thus, ICGA is the more appropriate modality for obtaining information on the entire fundus [68].

**Retinal SD-OCT**

In acute initial-onset VKH disease, the advent of SD-OCT dramatically increased the precision of analyzing exudative retinal detachments. In 2004, Maruyama and Kishi distinguished two types of SRDs: a true, complete retinal detachment on one side, and detachments that...
separated the outer retinal layers from the intraretinal fluid [69]. Later studies conducted in the same institution showed that the multi-lobular dye pooling detected with FA was due to subretinal septa formed from inflammatory products, such as fibrin [70]. Moreover, SD-OCT provided more precise morphological information about splitting in the photoreceptor layer in exudative retinal detachments (Fig. 6) [71]. One study clearly showed intraretinal splitting at the junction of the inner and outer segments [72]. Choroidal/RPE folds were described as a frequent sign in patients with acute initial-onset VKH disease [73, 74]. This manifestation was related to more severe disease and longstanding inflammation in choroidal tissue [74, 75].

In chronic VKH, SD-OCT could show signs of subclinical inflammation, such as macular edema and early signs of macular complications [52]. Regardless of the specific OCT findings, the most practical aspect of SD-OCT is its ability to provide close monitoring of lesion remission after (aggressive) treatment.

**Choroidal EDI-OCT**

EDI-OCT is a non-invasive imaging modality that makes it possible to analyze choroidal involvement in VKH. Depending on the stage of the disease, choroidal thickness is either increased (in early-stage disease) or reduced (in late-stage and/or ill-treated disease). In the early disease stage, EDI-OCT could clearly show increases in choroidal thickness (Fig. 7), and the thickness was shown to decrease progressively with treatment. However, during corticosteroid tapering, a rebound in the sub-foveal choroidal thickness was observed in some cases of recurrence [76, 77]. In the acute stage of VKH, choroidal thickness was found to decrease at the expense of the outer choroid. Consequently, it was suggested that the primary target of the disease might be located in that layer [78]. In the absence of appropriate treatment, long periods of uncontrolled disease may cause a reduction in choroidal thickness over time, due to choroidal atrophy. Several reports have shown choroidal thinning in convalescent or chronically evolving disease [79, 80]. Moreover, in the late stages of VKH, choriocapillaris layer disruptions were described [81].

EDI-OCT is a valuable diagnostic and monitoring modality for initial-onset VKH disease. It provides information on choroidal thickness, and hence, on inflammatory choroidal infiltration [76, 77]. In the very early stage of VKH, the choroid thickens in proportions that cannot be measured. With treatment, choroidal thickness progressively decreases, and this thickness is a useful parameter for monitoring disease evolution. In the subacute phase of VKH, EDI-OCT provides less precise information than ICGA, because the range of EDI-OCT is limited to the posterior pole [49, 68, 82, 83]. However, in post-acute disease, choroidal thickness can result from disease remission, in some areas of the choroid, and from reactivation, in other areas. Thus, these measurements are difficult to interpret. However, several reports have shown that EDI-OCT could indicate subclinical reactivations before they were clinically apparent [84, 85] and it could indicate atrophic sunset glow fundus evolution [86]. In addition, some authors demonstrated that the level of anterior segment inflammation was moderately correlated to the sub-foveal choroidal thickness [87]. Nevertheless, as the choroid becomes thinner, changes in...
the sub-foveal choroidal thickness become more variable during recurrences [86, 87].

Assessing choroidal involvement and early VKH diagnosis

ICGA became available in the mid-1990s [88]. The advent of ICGA provided substantial progress in appraisals of posterior uveitis because it allowed precise evaluations of inflammation in the choroidal compartment. These evaluations were previously not possible or only roughly possible with echography [89]. For the first time, with ICGA, the clinicopathology of primary or secondary choroiditis entities could be clarified, due to the ability to distinguish stromal choroiditis from choriocapillaritis [90]. The principles of ICGA that applied to posterior uveitis were defined in 1999 [91]. Four main signs of stromal choroiditis (including VKH disease) were identified

(See figure on next page.)

**Fig. 6** SD-OCT findings in the acute phase of VKH. Choroidal folds and exudative retinal detachments that split the photoreceptor layer

**Fig. 7** EDI-OCT findings in course of VKH, from presentation to a 12-month follow-up. A At presentation, the choroid is too thick to be measured (note choroidal folds). B after 2 weeks, the limit of the choroidal space can again be recognized, but choroidal thickness is increased (mean subfoveal thickness = 525 ± 13.1 μm). C-E the choroidal thickness progressively decreased; C after 2 months, the choroidal thickness was 493.3 ± 23.5 μm; D after 8 months, the choroidal thickness was 460.3 ± 24.5 μm; and E at 12 months, the choroidal compartment is thinner than normal (224 ± 43.2 μm).
Fig. 7 (See legend on previous page.)
ICGA is crucial for evaluating stromal choroiditis (like VKH) for several reasons, including: (1) it shows the primary lesion; i.e., inflammatory choroidal infiltration (94), (2) it gives a global, pan-fundal overview of the stromal lesions, and therefore, it is superior to EDI-OCT (which is mostly limited to the posterior pole) [68, 82]; and (3) it allows identification of subclinical lesions, which provides (a) an early diagnosis and (b) a means to monitor the subclinical evolution of the disease [95, 96]. ICGA monitoring of subclinical choroiditis can ensure zero tolerance of inflammation after treating initial-onset disease [97]; and thus, it enables a cure for the disease in a substantial proportion of patients [4, 37]. Consequently, ICGA is clearly the gold standard for appraisals and follow-ups in VKH disease, however EDI-OCT should be especially considered in those geographic areas where ICGA is not fully available.

**Additional imaging methods for diagnosing and monitoring VKH disease**

Recently, new imaging methods have been applied to VKH disease that are of some interest in research, but they are not directly relevant for practical diagnostic and follow-up purposes. These methods are either not standardized, or they are not appropriate, mainly because they were not designed to provide information on choroidal stroma. The two modalities that have been applied to many clinical entities, including VKH, are blue light fundus autofluorescence (BL-FAF) [98] and OCT-angiography (OCT-A) [99].

BL-FAF is very useful for assessing diseases that involve the RPE, the photoreceptors, or the choriocapillaris. However, VKH does not primarily involve the RPE or choriocapillaris. These structures are involved secondarily, due to underlying choroidal swelling and overlying exudative detachments. Thus, BL-FAF findings do not directly reflect the morphological changes caused by VKH; instead, those findings depend on the severity of choroiditis or exudative detachment [100]. Consequently, BL-FAF cannot be used for routine assessments, unlike OCT and ICGA, which provide direct assessments of primary lesions. BL-FAF findings are difficult to interpret because the lesions depend on the stage and evolution of the disease, and they are not essential for routine practical purposes. However, BL-FAF can provide information on the disease stage and disease severity, particularly in chronic disease.

We identified less than five studies on VKH in the PubMed database that used “OCT-A” in the title [99]. OCT-A can detect secondary choriocapillaris/RPE loss and inflammatory choroidal neovascularization. Thus, both BL-FAF and OCT-A are useful for documenting potential secondary evolutions of the disease, but not for routine primary systematic evaluations of VKH disease intensity or follow-up. Accordingly, although it is an overstatement to speak of the role of OCT-A in the diagnosis and management of VKH, its value lies in documenting some of the consequences of stromal choroiditis on neighboring structures.

**Table 1** ICG angiographic signs in stromal choroiditis

|   |                                                                                           |
|---|--------------------------------------------------------------------------------------------|
| 1 | Hypofluorescent dark dots (HDDs)                                                           |
| 2 | Indistinct choroidal vessel (Fuzziness of choroidal vessels)                               |
| 3 | Diffuse late choroidal hyperfluorescence (partially hiding HDDs)                           |
| 4 | ICGA disc hyperfluorescence (in severe choroiditis)                                       |

**Practical diagnostic criteria for early VKH diagnosis**

With the availability of effective inflammation-suppressive treatment [101, 102], it became necessary to develop systematized, effective, diagnostic criteria to ensure that therapy could be introduced as soon as possible. In 1978, Seiji Sugiura’s VKH diagnostic criteria were published in the English language [103]. Thereafter, in 1980, a new definition of VKH diagnostic criteria was attempted in a country (United States) where the incidence of VKH was rare [104]. In 1999, a workshop was held under the auspices of the University of California and the University of Southern California with the aim of revising the diagnostic criteria for VKH [5]. However, these two sets of criteria were insufficient, due to the lack of sensitive investigative procedures for choroiditis and the inadequate separation between initial-onset and chronic forms of the disease.

In the 1990s, the development of ICGA made it possible to image the choroidal compartment, which enabled precise, reliable assessments of choroidal inflammation [42]. Because VKH is primarily a choroidal inflammatory disease, ICGA substantially improved the appraisal of VKH disease. ICGA provided unparalleled sensitivity for diagnosing, monitoring, and following the evolution of VKH disease [90]. Recently, more precise criteria were defined and we moved one step closer to establishing adequate, simple diagnostic criteria for VKH. These criteria took advantage of novel, sensitive imaging methods for investigating the choroid [39]. Importantly, separate criteria were defined for initial-onset (Table 2) and chronic VKH disease (Table 3).
**VKH management**

In recent years, VKH treatment paradigms have evolved substantially. Koyanagi’s groundbreaking publication precisely described the natural evolution of the disease in the absence of treatment [10]. When corticosteroid treatment became available in the 1950s [101, 102, 106, 107], the perception of VKH evolution was modified from a non-treatable to a chronically evolving disease.

---

**Fig. 8** Four main signs detected with ICGA in acute initial-onset VKH disease. **A** Hyperfluorescent disc (usually hypofluorescent on ICGA), which indicates severe inflammation. **B** Early hyperfluorescent vessels. **C** Numerous, regularly distributed hypofluorescent dark dots (HDDs), evenly sized, over the whole fundus, is the most demonstrative and quantifiable ICGA sign. **D** (Top) Fuzzy, indistinct choroidal vessels represent the fourth ICGA sign; (Bottom) After 3 days of intravenous methylprednisolone treatment, the course and structure of choroidal vessels are again distinctly visible.
After that, it became clear that two forms of VKH should be distinguished, the initial-onset disease and the insufficiently treated chronic disease. Indeed, in some cases, corticosteroid therapy provided a cure, but in a large proportion of cases, corticosteroid therapy could not completely cure the disease or avert chronic evolution [53]. An increasing number of clinicians suggested that additional, non-steroidal immunosuppressive agents were needed [108, 109].

This review was not designed to describe in detail the new approaches for VKH treatment, which have been described recently [31, 39]. Instead, here, we summarize the following general principles:

1. Corticosteroid monotherapy was shown to be insufficient in arresting the disease, even when given early and in high doses [53].
2. A combination of steroidal and non-steroidal immunosuppression, as first-line therapy, could prevent chronic evolution and cure the disease [37]. In a study that included 974 patients, corticosteroid monotherapy was compared to combined steroidal and non-steroidal immunosuppression. They found that chronic evolution was reduced from 44% to 2.3% in the combined treatment group [4].
3. Early treatment is another pre-requisite for successful management of VKH [32, 110]. It is crucial to treat within the therapeutic window of opportunity. The window of opportunity for initial-onset VKH is between 2 and 4 weeks, but it is probably different for each patient. Studies that aim to determine a more precise time interval are presently ongoing.
4. Therapy should aim for zero tolerance of choroidal inflammation, monitored with ICGA or EDI-OCT [95, 97].
5. Because efficient therapy can vary from patient to patient, therapies are administered in trial-and-error mode, facilitated by closely monitoring the evolution of choroidal lesions with ICGA [82].
Conclusion
At 115 years after the first description of VKH, we currently understand its course and behavior. We can diagnose it early, treat it efficiently, and monitor it precisely.

Abbreviations
BL‑FAF: Blue light fundus autofluorescence; EDI‑OCT: Enhanced depth imaging OCT; FA: Fluorescein angiography; HLA: Human leukocyte antigens; IC卫: Indocyanine green angiography; IL: Interleukin; MHC: Major histocompatibility complex; OCT: Optical coherence tomography; OCT‑A: OCT‑angiography; OD‑SRD: Optic‑disc swelling SRD; PBMCs: Peripheral blood mononuclear cells; RPE: Retinal pigment epithelium; SD‑OCT: Spectral domain OCT; SRDs: Serous retinal detachments; Th: T helper cells; TRP: Tyrosinase‑related proteins; TYR: Tyrosinase; UWF‑FA: Ultra‑wide field FA; VKH: Vogt‑Koyanagi‑Harada.

Acknowledgements
Not Applicable.

Authors’ contributions
CAU and CPH conceptualized the manuscript; CAU, CPH, MT, AS, LECR, YU, LC, IP drafted the manuscript and read and approved the final version of the manuscript.

Funding
This study was supported by the National Agency for Research and Development (ANID) grant Fondecyt Regular No. 1212038 (given to CAU) and Fondecyt Regular No. 11191215 (given to LC).

Availability of data and materials
Not Applicable.

Declarations

Ethics approval and consent to participate
Not Applicable.

Consent for publication
Not Applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Laboratory of Ocular and Systemic Autoimmune Diseases, Faculty of Medicine, University of Chile, Santiago, Chile. 2 Department of Ophthalmology, University of Chile, Santiago, Chile. 3Facultad de Medicina, Clínica Alemana‑Universidad del Desarrollo, Santiago, Chile. 4Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialised Care (COS), Lausanne, Switzerland. 5Department of Ophthalmology, National Defense Medical College, Tokorozawa, Saitama, Japan. 6Hospital Universitario Austral, Hospital de Clínicas de la Universidad de Chile, Santiago, Chile. 7Inflammatory Eye Disease Clinic, Dr. Luis Sanchez Bulnes Hospital, Asociación para Evitar la Ceguera en México (APEC), Mexico City, CDMX, Mexico. 8Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan. 9Service de Oftalmología, Hospital Clínico Universidad de Chile, Santiago, Chile.

Received: 15 November 2021   Accepted: 7 April 2022
Published online: 12 May 2022

References
1. Vogt A (1906) Frühzeitiges ergraben der Zilien und Bemerkungen über den sogenannten plötzlichen Eintritt dieser Veränderung. Klin Monatsbl Augenhkld 44:228–242
2. Herbst CP, Mochizuki M (2007) Vogt‑Koyanagi‑Harada disease: inquiry into the genesis of a disease name in the historical context of Switzerland and Japan. Int Ophthalmol 27:67–79. https://doi.org/10.1007/s10792‑007‑9083
3. Lavezzo MM, Sakata VM, Morita C, Rodrigues EE, Abdallah SF, da Silva FT et al (2016) Vogt‑Koyanagi‑Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis 11:29. https://doi.org/10.1186/s13023‑016‑0412‑4
4. Papasavvas I, Tugal‑Tutkun I, Herbst CP Jr (2020) Vogt‑Koyanagi‑Harada is a curable autoimmune disease: early diagnosis and immediate dual steroidal and non‑steroidal immunosuppression are crucial prerequisites. J Curr Ophthalmol 32(4):310–314. https://doi.org/10.4103/JOCO.JOCO_190_20
5. Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes‑Garcia L et al (2001) Revised diagnostic criteria for Vogt‑Koyanagi‑Harada disease: report of an international committee on nomenclature. Am J Ophthalmol 131(5):647–652. https://doi.org/10.1016/s0002‑9394(01)00925‑4
6. Yang P, Ren Y, Li B, Fang W, Meng Q, Klijstra A (2007) Clinical characteristics of Vogt‑Koyanagi‑Harada syndrome in Chinese patients. Ophthalmology. 114:606–614. https://doi.org/10.1016/j.ophtha.2006.07.040
7. da Silva FT, Damico FM, Marin ML, Goldberg AC, Hirata CE, Takushi PH et al (2009) Revised diagnostic criteria for vogt‑koyanagi‑harada disease: considerations on the different disease categories. Am J Ophthalmol 147(2):339–345.e5. https://doi.org/10.1016/j.ajo.2008.08.034
8. Komoto J (1911) Ueber Vitiligo und Auge. Klin Monatsbl Augenheilkd 49:139–142
9. Koyanagi Y (1914) Nippon Ganka Gakkai Zasshi. Klin Monatsbl Augenheilk 18:1188
10. Koyanagi Y (1929) Dysakusis, Alopecia and Poliosis bei schwerer Uveitis nicht traumatischen Ursprungs. Klin Monatsbl Augenheilkd 82:194–211
11. Harada E (1926) Beitrag zur klinischen Kenntnis von nichteitriger Chorioiditis (choroiditis diffusa acuta). Acta Soc Ophthalmol Jpn (Nippon Ganka Gakkai Zasshi) 30:356–378
12. Babel J (1932) Syndrome de Vogt‑Koyanagi (Uveite bilateral, poliosis, alopecie, vitiligo et dysacousie). Schweiz Med Wochenschr 62:1136–1140
13. Ooba N (2006) Vogt‑Koyanagi‑Harada syndrome—historical changes in the eponym. Nippon Ganka Gakkai Zasshi 110(2):144–149
14. Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S (2000) Tyrosinase‑like family proteins are antigens specific to Vogt‑Koyanagi‑Harada disease. J Immunol 165(12):7322–7329. Epub 2000/12/20. https://doi.org/10.4049/jimmunol.165.12.7323
15. Gocho K, Kondo I, Yamaki K (2001) Identification of autoreactive T cells in Vogt‑Koyanagi‑Harada disease. Invest Ophthalmol Vis Sci 42(9):2004–2009
16. Damico FM, Cunha‑Neto E, Goldberg AC, Iwai IK, Marin ML, Ham‑mer J et al (2005) T‑cell recognition and cytokine profile induced by melanocyte epitopes in patients with HLA‑DRB1*0405‑positive and ‑negative Vogt‑Koyanagi‑Harada uveitis. Invest Ophthalmol Vis Sci 46(7):2465–2471. https://doi.org/10.1167/iovs.04‑1273
17. Sugita S, Takase H, Taguchi C, Imai Y, Kamoi K, Kawauchi T et al (2006) Ocular infiltrating CD4+ T cells from patients with Vogt‑Koyanagi‑Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci 47(6):2547–2554. https://doi.org/10.1167/iovs.05‑1547 Epub 2006/05/26. PubMed PMID: 16723469
18. Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S (2000) Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in Lewis rats. Exp Eye Res 71(4):361–369. https://doi.org/10.1006/exer.2000.0893
19. Kamal S, Kemdt CC, Lappin SL. Genetics, Histocompatibility Antigen. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan.‑. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541023/
20. Sakamoto T, Murata T, Inomata H (1991) Class II major histocompatibility complex on melanocytes of Vogt‑Koyanagi‑Harada disease. Arch Ophthalmol 109(9):1270–1274. https://doi.org/10.1001/archophthalmol.1991.01080090006030
21. Shindo Y, Inoko H, Yamamoto T, Ohno S (1994) HLA‑DRB1 typing of Vogt‑Koyanagi‑Harada’s disease by PCR‑RFLP and the strong
association with DRB1*0405 and DRB1*0410. Br J Ophthalmol 78(3):223–226. https://doi.org/10.1136/bjo.78.3.223
22. Chi W, Yang P, Li B, Wu C, Jin H, Zhu X et al (2007) IL-23 promotes CD4+ T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. J Allergy Clin Immunol 119(6):1218–1224. https://doi.org/10.1016/j.jaci.2007.01.010
23. Li F, Yang P, Liu X, Wang C, Hou S, Kijlstra A (2010) Upregulation of interleukin 21 and promotion of interleukin 17 production in chronic or recurrent Vogt-Koyanagi-Harada disease. Arch Ophthalmol 128(11):1449–1454. https://doi.org/10.1001/archophthalmol.2010.265
24. Wang C, Tian Y, Li B, Xiao Y, Ye Z, Li F et al (2012) Decreased IL-27 expression in association with an increased Th17 response in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 53(8):4668–4675. https://doi.org/10.1167/iovs.11-89863
25. Commodoro AG, Peron JP, Genie J, Arsalanian C, Sanches L, Muccillo C et al (2010) IL-10 and TGF-beta immunoregulatory cytokines rather than natural regulatory T cells are associated with the resolution phase of Vogt-Koyanagi-Harada (VKH) syndrome. Scand J Immunol 72(1):31–37. https://doi.org/10.1111/j.1365-3083.2010.02401.x
26. Liang L, Peng XY, Wang H (2019) Th lymphocyte subsets in patients with Vogt-Koyanagi-Harada disease. Int J Ophthalmol 12(2):207–211. https://doi.org/10.18240/ijio.2019.02.04
27. Elahi S, Herbert CP Jr (2019) Vogt-Koyanagi-Harada disease and birdshot retinochoroiditis. Similarities and differences. A glimpse into clinicopathologic and clinical characteristics of stromal choroiditis, a perspective and a review. Kin Monbl Augenheilkd 236:492–510. https://doi.org/10.1055/a-0829-6763
28. Buch MH, Eyre S, McGonagle D (2021) Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol 17(1):17–33. https://doi.org/10.1038/s41584-020-00541-7
29. Palman J, Shoop-Worrall S, Hyrich K, McDonagh JE (2018) Update on the epidemiology, risk factors and disease outcomes of juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol 32:206–222. https://doi.org/10.1016/j.berh.2018.10.004
30. Lublin FD (2014) New multiple sclerosis phenotypic classification. Eur Neurol 72(Suppl 1):1–5. https://doi.org/10.1159/000367614
31. Herbert CP Jr, Al Bloushi AF, Herbort CP, Abu El-Asrar AM, Gikandi PW (2021) Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement. Int Ophthalmol. https://doi.org/10.1007/s10792-021-02198-6
32. Abu El-Asrar AM, Al Bloushi AF, Herbort CP (2021) Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye. J Ophthalmic Inflamm Infect 11(1):6. https://doi.org/10.1186/s12348-021-00237-3
33. Al Bloushi AF, Herbert CP, Abu El-Asrar AM (2021) Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement. Int Ophthalmol. https://doi.org/10.1007/s10792-021-01992-0
34. Bouchenaki N, Herbort CP, Abu El-Asrar AM, Al-Mezaine HS, Al-Muammar A, Kangave D (2013) Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol 91(6):e486–e493. https://doi.org/10.1111/aos.12127
35. Wang, Zhou H, Yang P, Huang X, Wang L, Kijlstra A (2008) Longitudinal quantification of aqueous flare and cells in Vogt-Koyanagi-Harada disease. Br J Ophthalmol 92(2):182–185. https://doi.org/10.1136/bjo.2007.129828
36. Papasavvas I, Herbert CP Jr (2021) Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye. J Ophthalmic Inflamm Infect 11(1):6. https://doi.org/10.1186/s12348-021-00237-3
37. Abu El-Asrar AM, Al Bloushi AF, Herbort CP (2021) Initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease presenting with unilateral exudative retinal detachment despite bilateral choroidal involvement. Int Ophthalmol. https://doi.org/10.1007/s10792-021-01989-6
38. Abu-Asramp MA, Gupta V, Hemachandran S, Herbert CP, Abu El-Asrar AM (2016) Indocyanine green angiographic findings in initial-onset acute Vogt-Koyanagi-Harada disease. Acta Ophthalmol 94(6):573–578. https://doi.org/10.1111/aos.12974
39. Murata T, Sako N, Takayama K, Harimoto K, Kanda K, Herbort CP, Takeuchi M (2019) Identification of underlying inflammation in Vogt-Koyanagi-Harada disease with sunset glow fundus by multiple analyses. J Ophthalmol 2019:3853794. https://doi.org/10.1155/2019/3853794
40. Okunuki Y, Tsubota K, Ketzka T, Goto H (2015) Differences in the clinical features of two types of Vogt-Koyanagi-Harada disease: serous retinal detachment and optic disc swelling. Jpn J Ophthalmol 59(2):103–108. https://doi.org/10.1007/s10384-014-0367-8
41. Nakayama M, Keino H, Watanabe T, Okada AA (2019) Clinical features and visual outcome of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol 103(2):274–278. https://doi.org/10.1136/bjophthalmol-2017-311691
42. Agarwal M, Radosavljevic A, Patnaik G, Rishi E, Pichi F (2020) Diagnostic value of optical coherence tomography in the early diagnosis of macular complications in chronic Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm:1–8. https://doi.org/10.1080/09273948.2020.18332 215
43. Sakata VM, da Silva FT, Hirata CE, Marin ML, Rodrigues H, Kalli J et al (2015) High rate of clinical recurrence in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Graefe Arch Clin Exp Ophthalmol 253(5):785–790. https://doi.org/10.1007/s00417-014-2904-2
44. Okuno S, Mimakawa R, Matsuda H (1988) Clinical studies of Vogt-Koyanagi-Harada’s disease. Jpn J Ophthalmol 32(3):334–343
55. Inomata H, Rao NA (2001) Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease. Am J Ophthalmol 131(5):607–614. https://doi.org/10.1016/s0002-9394(00)00851-5

56. Abu El-Asrar AM, Al Mudhaiyan T, Al Najashi AA, Hemachandran S, Hariz R, Mousa A, Al-Muammar A (2017) Chronic recurrent Vogt-Koyanagi-Harada disease and development of ‘Sunset glow Fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm 25(4):475–485. https://doi.org/10.1080/09273948.2016.1139730

57. Huang G, Peng J, Ye Z, Klijstra A, Zhang D, Yang P (2018) Multiplespectral image analysis in Vogt-Koyanagi-Harada disease. Acta Ophthalmol 96(4):411–419. https://doi.org/10.1111/aos.13606

58. Abu El‑Asrar AM, Al‑Mudhaiyan T, Al‑Najashi AA, Hemachandran S, Hariz R, Mousa A, Al‑Muammar A (2017) Chronic recurrent Vogt‑Koyanagi‑Harada disease and development of ‘Sunset glow Fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm 25(4):475–485. https://doi.org/10.1080/09273948.2016.1139730

59. Abe H, Inomata H, Sasaki K, Omo Y, Sato A, Suzuki S, Matsuda H, Yamauchi H (2012) Enhanced retinal thickness imaging in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 56(6):641–645. https://doi.org/10.1007/s10792-012-9407-7

60. Chee SP, Jap A, Cheung CM (2010) The prognostic value of angiography and OCT choroidal thickness and SUN vitreous haze evaluation in stromal choroiditis: a case series. J Curr Ophthalmol 31(2):180–187. https://doi.org/10.1016/j.jocjo.2012.06.006

61. Fardeau C, Chau Tran TH, Hharbi B, Cassoux N, Bodagui B, LeHoang P (2007) Retinal fluorescein and indocyanine green angiography and optical coherence tomography in successive stages of Vogt-Koyanagi-Harada disease. Int Ophthalmol 27(2–3):163–172. https://doi.org/10.1007/s10792-006-9024-7

62. Fabro F, Herbort CP (2018) Need for quantitative measurement methods for posterior uveitis: comparison of dual FA/ICGA angiography, EDI-OCT choroidal thickness and SUN vitreous haze evaluation in stromal choroiditis. Clin Monatal Augenheilkdl 203(5):424–435. https://doi.org/10.1055/s-0043-124966

63. Kambara H, Sato Y, Nakanishi T, Nishida K (2012) Enhanced depth imaging optical coherence tomography of choroidal folds in acute‑stage vogt‑koyanagi‑harada disease using high‑resolution optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 250(7):1089–1095. https://doi.org/10.1007/s00417-011-1910-7

64. Kato Y, Yamamoto Y, Tabuchi H, Fukushima A (2013) Retinal pigment epithelium folds as a diagnostic finding of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 57(1):90–94. https://doi.org/10.1017/jo.2012.69

65. Tsuibo K, Nakai K, Iwashashi C, Gomi F, Ikuno Y, Nishida K (2015) Analysis of choroidal folds in acute Vogt-Koyanagi-Harada disease using high‑penetration optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 253(6):959–964. https://doi.org/10.1007/s00417-015-2494-9

66. Koyanagi‑Harada disease and development of ‘Sunset glow Fundus’ predict worse retinal sensitivity. Ocul Immunol Inflamm 25(4):475–485. https://doi.org/10.1080/09273948.2016.1139730

67. Nakayama Y, Keino H, Okada AA, Watanabe T, Taki W, Inoue M, Hirakata A (2012) Enhanced depth imaging optical coherence topography of the choroid in Vogt-Koyanagi-Harada disease. Retina. 32(10):2061–2069. https://doi.org/10.1097/IAE.0b013e318256205a

68. Hirooka K, Saito W, Namiba K, Mizuuchi K, Iwata D, Hashimoto Y, Ishida S (2015) Significant role of the choroidal outer layer during recovery from choroidal thickening in Vogt-Koyanagi-Harada disease patients treated with systemic corticosteroids. BMC Ophthalmol 15:181. https://doi.org/10.1186/s12886-015-0171-3
90. Herbort CP, Mantovani A, Papadia M (2012) Use of indocyanine green angiography in uveitis. Int Ophthalmol Clin 52:13–31. https://doi.org/10.1097/OIO.0b013e318265d48b
91. Herbort CP, LeHoang P, Guex-Crosier Y (1998) Schematic interpretation of indocyanine green angiography in posterior uveitis using a standard angiographic protocol. Ophthalmology. 105(3):432–440. https://doi.org/10.1016/S0161-6420(98)93024-X
92. Herbort CP, Mantovani A, Bouchenaki N (2007) Indocyanine green angiography in Vogt-Koyanagi-Harada disease: angiographic signs and utility in patient follow-up. Int J Ophthalmol 27(2–3):173–182. https://doi.org/10.1007/s10792-007-0906-y
93. Miyanaga M, Kawaguchi T, Miyata K, Horie S, Mochizuki M, Herbort CP (2010) Indocyanine green angiography findings in initial acute pretreatment Vogt-Koyanagi-Harada disease in Japanese patients. Jpn J Ophthalmol 54(5):377–382. https://doi.org/10.1007/s10384-010-0853-6
94. Herbort CP Jr, Mantovani A, Tugal-Tutkun I, Papasavvas I (2021) Classification of non-infectious and/or immune mediated choroiditis: a brief overview of the essentials. Diagnostics (Basel) 11(6):939. https://doi.org/10.3390/diagnostics11060939
95. Kawaguchi T, Horie S, Bouchenaki N, Ohno-Matsui K, Mochizuki M, Herbort CP (2010) Suboptimal therapy controls clinically apparent disease but not subclinical progression of Vogt-Koyanagi-Harada disease. Int Ophthalmol 30(1):41–50. https://doi.org/10.1007/s10792-008-9288-1
96. Bacsal K, Wen DS, Chee SP (2008) Concomitant choroidal inflammation during anterior segment recurrence in Vogt-Koyanagi-Harada disease. Am J Ophthalmol 145(3):480–486. https://doi.org/10.1016/j.ajo.2007.10.012
97. Bouchenaki N, Herbort CP (2011) Indocyanine green angiography guided management of vogt-koyanagi-harada disease. J Ophthalmic Vis Res 6(4):241–248
98. Koizumi H, Matsumiya K, Kinoshita S (2010) Blue light and near-infrared fundus autofluorescence in acute Vogt-Koyanagi-Harada disease. Br J Ophthalmol 94(11):1499–1505. https://doi.org/10.1136/bjo.2009.164665
99. Aggarwal K, Agarwal A, Mahajan S, Invernizzi A, Mandadi SKR, Singh R et al (2018) OCTA study group. The role of optical coherence tomography angiography in the diagnosis and Management of Acute Vogt-Koyanagi-Harada Disease. Ocul Immunol Inflamm 26(1):142–153. https://doi.org/10.1080/09273948.2016.1195001
100. Morita C, Sakata VM, Rodriguez EE, Abdallah SF, Lavezzo MM, da Silva FT et al (2016) Fundus autofluorescence as a marker of disease severity in Vogt-Koyanagi-Harada disease. Acta Ophthalmol 94(8):e820–e821. https://doi.org/10.1111/aos.13147
101. Reed H, Lindsay A, Silversides JL, Speakman J, Monckton G, Rees DL (1958) The uveo-encephalitic syndrome or Vogt-Koyanagi-Harada disease. Can Med Assoc J 79(6):451–459
102. Ohno S, Char DH, Kimura SJ, O'Connor GR (1977) Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 83(5):735–740. https://doi.org/10.1016/0002-9394(77)90142-8
103. Sugura S (1978) Vogt-Koyanagi-Harada Disease. Jpn J Ophthalmol 22:9–35
104. Snyder DA, Tessler HH (1980) Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 90(1):69–75
105. Valenzuela RA, Flores I, Pujol M, Llanos C, Carreño E, Rada G et al (2020) Definition of uveitis refractory to treatment: a systematic review in the absence of a consensus. Ocul Immunol Inflamm 4:1–6. https://doi.org/10.1080/09273948.2020.1793369
106. Masuda K, Tanishima T (1969) Early treatment of Harada's disease. Jpn J Ophthalmol 23:553
107. Kotake S, Ohno S (1984) Pulse methyl prednisolone therapy in the treatment of Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol 28:1053–1058
108. Paredes I, Ahmed M, Foster CS (2006) Immunomodulatory therapy for Vogt-Koyanagi-Harada patients as first-line therapy. Ocul Immunol Inflamm 14(2):87–90. https://doi.org/10.1080/09273940500536766
109. Abu El-Asrar AM, Hemachandran S, Al-Mezaine HS, Kangave D, Al-Muammar AM (2012) The outcomes of mycophenolate mofetil therapy combined with systemic corticosteroids in acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol 90(8):e603–e608. https://doi.org/10.1111/j.1755-3768.2012.02498.x
110. Sheu SJ, Kou HK, Chen JF (2003) Prognostic factors for Vogt-Koyanagi-Harada disease. J Chin Med Assoc 66(3):148–154

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.